KR102594943B1 - 혈관신생 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자 - Google Patents

혈관신생 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자 Download PDF

Info

Publication number
KR102594943B1
KR102594943B1 KR1020227039674A KR20227039674A KR102594943B1 KR 102594943 B1 KR102594943 B1 KR 102594943B1 KR 1020227039674 A KR1020227039674 A KR 1020227039674A KR 20227039674 A KR20227039674 A KR 20227039674A KR 102594943 B1 KR102594943 B1 KR 102594943B1
Authority
KR
South Korea
Prior art keywords
antibody
leu
ser
antigen
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227039674A
Other languages
English (en)
Korean (ko)
Other versions
KR20230028225A (ko
Inventor
다카요시 다나카
유지 사노
유미코 가와이
Original Assignee
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤 filed Critical 추가이 세이야쿠 가부시키가이샤
Priority to KR1020237036198A priority Critical patent/KR20230152789A/ko
Publication of KR20230028225A publication Critical patent/KR20230028225A/ko
Application granted granted Critical
Publication of KR102594943B1 publication Critical patent/KR102594943B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020227039674A 2020-06-19 2021-06-18 혈관신생 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자 Active KR102594943B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237036198A KR20230152789A (ko) 2020-06-19 2021-06-18 혈관신생 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-106501 2020-06-19
JP2020106501 2020-06-19
PCT/JP2021/023149 WO2021256555A1 (ja) 2020-06-19 2021-06-18 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237036198A Division KR20230152789A (ko) 2020-06-19 2021-06-18 혈관신생 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자

Publications (2)

Publication Number Publication Date
KR20230028225A KR20230028225A (ko) 2023-02-28
KR102594943B1 true KR102594943B1 (ko) 2023-10-27

Family

ID=79268097

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227039674A Active KR102594943B1 (ko) 2020-06-19 2021-06-18 혈관신생 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자
KR1020237036198A Pending KR20230152789A (ko) 2020-06-19 2021-06-18 혈관신생 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237036198A Pending KR20230152789A (ko) 2020-06-19 2021-06-18 혈관신생 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자

Country Status (15)

Country Link
US (1) US20230235056A1 (https=)
EP (1) EP4186527A4 (https=)
JP (2) JP7250219B2 (https=)
KR (2) KR102594943B1 (https=)
CN (1) CN115768478A (https=)
AU (1) AU2021292932A1 (https=)
BR (1) BR112022025536A2 (https=)
CA (1) CA3180951A1 (https=)
CL (1) CL2022003622A1 (https=)
CR (1) CR20230014A (https=)
IL (1) IL299127A (https=)
MX (1) MX2022015764A (https=)
PE (1) PE20230435A1 (https=)
TW (1) TW202214286A (https=)
WO (1) WO2021256555A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
WO2025120867A1 (en) * 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
TW202539742A (zh) * 2024-02-08 2025-10-16 大陸商上海翰森生物醫藥科技有限公司 抗體藥物偶聯物和抗ｖｅｇｆ抗體的聯合應用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773719A (en) 1966-12-06 1973-11-20 Hoffmann La Roche 2-aminoxy-2'-acyl-acetanilide
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
EP2144931A2 (en) 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
AU2015244814B2 (en) 2014-04-07 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US11072666B2 (en) * 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
WO2018038046A1 (ja) 2016-08-22 2018-03-01 中外製薬株式会社 ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
JP7784795B2 (ja) * 2016-11-15 2025-12-12 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
US20200101108A1 (en) * 2017-03-31 2020-04-02 The Board Of Trustees Of The Le-Land Standford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Immunol Immunother(2007), 56(10), pp1637-1644(2007.04.05.) 1부.*

Also Published As

Publication number Publication date
CA3180951A1 (en) 2021-12-23
BR112022025536A2 (pt) 2023-01-17
KR20230152789A (ko) 2023-11-03
EP4186527A4 (en) 2024-07-17
JPWO2021256555A1 (https=) 2021-12-23
CR20230014A (es) 2023-02-17
PE20230435A1 (es) 2023-03-08
US20230235056A1 (en) 2023-07-27
WO2021256555A1 (ja) 2021-12-23
IL299127A (en) 2023-02-01
JP2023078311A (ja) 2023-06-06
EP4186527A1 (en) 2023-05-31
KR20230028225A (ko) 2023-02-28
JP7250219B2 (ja) 2023-03-31
CL2022003622A1 (es) 2023-06-23
AU2021292932A1 (en) 2023-01-05
TW202214286A (zh) 2022-04-16
MX2022015764A (es) 2023-01-19
CN115768478A (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
JP7242760B2 (ja) ＴＧＦ－β及びＰＤ－１の阻害物質を使用する癌の治療法
KR101862236B1 (ko) 항-ｃｘｃｌ13 항체 및 이의 이용 방법
WO2018177220A1 (zh) 抗ox40抗体及其用途
KR102594943B1 (ko) 혈관신생 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자
HK1258249A1 (zh) 用於测定icos表达的基因标志
JP2022514179A (ja) 新規アゴニスト抗ｔｎｆｒ２抗体分子
KR102486064B1 (ko) 사이토카인 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자
JP2022512905A (ja) 新規アンタゴニスト抗ｔｎｆｒ２抗体分子
EP4245321A1 (en) Combination of antibody-drug conjugate with anti-sirpalpha antibody
KR20220035150A (ko) 특정 환자에서 암의 치료를 위한 항체 조합물
WO2019242619A1 (zh) 全人源的抗lag-3抗体及其应用
JP2022505144A (ja) Ｈｅｒ２ ｓ３１０ｆ特異的な抗原結合分子
KR102716165B1 (ko) 항-b7s1 폴리펩티드 및 이의 용도
JP2023554422A (ja) がんの治療のための多重特異性抗体
TW202423987A (zh) 抗ccr8抗體及其應用
CN119403829A (zh) 对于肿瘤抗原特异性的抗体和cd47抑制剂的组合
HK40082394A (en) Anti-t cell antigen-binding molecule for use in combination with angiogenesis inhibitor
CN117203241A (zh) 抗Siglec15抗体及其用途
HK40064168A (en) Anti-t cell antigen-binding molecule to be used in combination with cytokine inhibitor
WO2024141014A1 (zh) Cd74的医药用途
JP2026058690A (ja) 抗ｕｌｂｐ２抗体
CN118339183A (zh) 组合中针对pd-l1和cd137的多特异性结合剂
HK40095521A (zh) 抗体的新型组合及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221114

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20230307

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230405

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230810

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231023

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231024

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231024

End annual number: 3

Start annual number: 1

PG1601 Publication of registration